Pharmafile Logo
Pharmafocus logo
Advanced Search

ibrance

Showing 15 posts of 15 posts found.

lilly_building_with_american_flag_web

Lilly’s Verzenio combo tops Pfizer’s Ibrance and is first CDK4/6 inhibitor to show benefit in HR+,HER2- early breast cancer

June 18, 2020
Research and Development Eli Lilly, Pfizer, Verzenio, breast cancer, ibrance

 

News

Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

January 15, 2020
Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …

News
pfizer_building_logo1_19

Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

November 28, 2019
Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …

News

Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation

July 11, 2019
Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma

Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …

News

FDA approves Pfizer’s Ibrance for advanced male breast cancer

April 5, 2019
Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma

The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …

News
pfizerbrussels_web

Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer

June 26, 2018
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma

Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …

News

NICE approves Novartis and Pfizer’s rival breast cancer drugs

November 16, 2017
Sales and Marketing Kisqali, Novartis, Pfizer, biotech, drugs, ibrance, pharma, pharmaceutical

NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of …

News

Pfizer secures expanded approval for Ibrance

April 3, 2017
Sales and Marketing Pfizer, ibrance

Pfizer has announced that FDA has approved its supplemental New Drug Application (sNDA) for Ibrance, meaning that the drug is …

News

Pfizer’s breast cancer drug gets EU approval

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Novartis, Pfizer, ibrance

Pfizer is celebrating the approval by the European Union of its breast cancer drug Ibrance, following a positive recommendation from …

News
novartis_outside_1

Novartis breast cancer drug secures FDA fast-track status

November 1, 2016
Manufacturing and Production, Sales and Marketing Novartis, Pfizer, ibrance, letrozole, riboclib

Novartis has announced that its product ribociclib (LEE011) has been granted fast-track review status as a first-line treatment of advanced …

News
novartis_building

Novartis’ new drug muscles in on Pfizer’s territory

October 10, 2016
Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib

A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …

News
pfizer_reflection

Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

August 2, 2016
Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …

News
pfizer_logo

Pfizer raised 100 US drug prices 1 January

January 12, 2016
Manufacturing and Production, Sales and Marketing Allergan, Drug pricing, Lyrica, Pfizer, ibrance, tax inversion

Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January,  in …

News

Pfizer breast cancer trial stopped following promising results

April 15, 2015
Sales and Marketing ASCO, FDA, Pfizer, ibrance, palbociclib

Regulators have stopped a Phase III clinical trial of Pfizer’s Ibrance early after it demonstrated improved survival in women with …

News

Pfizer gets early approval for breast cancer drug

February 4, 2015
Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib

The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024